Effect of propranolol in retinopathy

Effect of oral propranolol in retinopathy of prematurity

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20100520003982N1

Enrollment

Registered

2019-01-23

Start date

2017-07-07

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinopathy of prematurity. Retinopathy of prematurity

Interventions

Intervention 1: Intervention group: Oral propranolol (prilol 10 from OLIDARU): Start with dose of 0.25 mg / kg / dday for two days , then take 0.5mg / kg / day every 12 hours until the patient needs

Eligibility

Sex/Gender

All

Age

182 Days to 224 Days

Inclusion criteria

Inclusion criteria: Preterm infants less than 1500 gr Preterm infants with gestational age greater than 26 weeks and less than 32 weeks Preterm infants with retinopathy grade I and II ROP Preterm infants admitted to NICU.

Exclusion criteria

Exclusion criteria: Congenital malformation cardiovascular problems except Patent Ductus Arteriosus (PAD) active sepsis Congenital infections (TORCH) Intraventricular hemorrhage (IVH) Grade II and III

Design outcomes

Primary

Measure	Time frame
Retinopathy process. Timepoint: On the 28th day after birth (before entering the study), every week until the end of study. Method of measurement: Indirect ophthalmoscopy.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAkram Mirjalili

Yazd University of Medical Sciences

dr.akrammirjalili@yahoo.com+98 35 3726 4881

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026